

Media Release

Zug, 1 October 2013

Favourable half-year profit of CHF 173 million expected

The net asset value (NAV) of the HBM Healthcare Investments share stood at CHF 87.16 as at 30 September 2013. Factoring in the par-value repayment that was made on 9 September 2013, this represents a 29.7% increase in value since the beginning of the financial year starting on 1st April 2013.

On the basis of this NAV, HBM Healthcare Investments expects a consolidated profit of about CHF 173 million for the first six months of the current financial year. A consolidated profit of CHF 18.6 million was generated during the corresponding prior-year period.

In addition to the IPOs of Ophthotech Corporation (CHF +75 million) and PTC Therapeutics (CHF +18 million), the major contributors to the latest half-year result were the public holdings in Basilea Pharmaceutica (CHF +57 million), Pacira Pharmaceuticals (CHF +29 million) and ChemoCentryx (CHF -12 million).

These figures are preliminary results, based on the current status of work on the closing financial statements. The quarterly report as at end-September 2013 will be published on 30 October 2013.

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments Ltd

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare
Investments

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com